Cytoskeletal Alterations That Confer Resistance to Anti-Tubulin Chemotherapeutics

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 14, 10 Issues, 2014


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 22nd of 58 in Chemistry, Medicinal
  • 85th of 202 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.939
5 - Year: 3.37

Cytoskeletal Alterations That Confer Resistance to Anti-Tubulin Chemotherapeutics

Author(s): Arun Kanakkanthara, Paul H. Teesdale-Spittle and John H. Miller


Abstract

Drugs that target microtubules are a successful class of anti-cancer agents that have been in clinical use for over two decades. Acquired resistance to these drugs, however, remains a serious problem. Microtubule alterations, such as tubulin mutations and altered ?-tubulin isotype expression, are prominent factors in development of resistance. Changes in actin and intermediate filament proteins can also mediate sensitivity to microtubule-targeting drugs. This review focuses on the mechanisms by which alterations in cytoskeletal proteins lead to drug resistance. This information will be helpful for improving the targeting of microtubule toxins.


Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 13
First Page: 1
Page Count: 1
DOI: 10.2174/1871520613666131125123056
Advertisement


Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science